deltatrials
Completed PHASE1/PHASE2 NCT01139216

Effect of TU-100 on Rectal Compliance, Rectal Sensation and Small Bowel and Colonic Transit in Females With Constipation

Effect of DAIKENCHUTO (TU-100), a Gastrointestinal Nerve Modulator, on Rectal Compliance, Rectal Sensation and Small Bowel and Colonic Transit in Female Patients With Functional Constipation

Sponsor: Cato Research

Conditions Colonic Transit Functional Constipation Gastric Emptying Rectal Compliance Rectal Sensation Small Bowel Transit Whole Gut Transit
Interventions Daikenchuto (TU-100) Placebo
Updated 7 times since 2017 Last updated: Jan 8, 2013 Started: Aug 31, 2010 Primary completion: Nov 30, 2012 Completion: Nov 30, 2012

Listed as NCT01139216, this PHASE1/PHASE2 trial focuses on Colonic Transit and Functional Constipation and remains completed. Sponsored by Cato Research, it has been updated 7 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE1_PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Aug 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cato Research
  • Tsumura USA
Data source: Tsumura USA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Rochester, United States